

## Clarification on Summary Information on the Funding and Supply of inclisiran (Leqvio®)

In April 2023, NHS England have provided updated information on the funding and supply of inclisiran as an option in the lipid management pathway. The introduction of inclisiran into the lipid management pathway in primary care is part of a broader programme of work being undertaken at NHS England that supports the use of all NICE approved treatments for lipid management.

[The funding and supply document is available here.](#)

The document is relevant for any healthcare professional involved in the prescribing, funding and supply of inclisiran and has been updated to include additional information on inclisiran funding for primary and secondary care (noting why changes have been made to secondary care funding) as well as new frequently asked questions and glossary sections.

Questions have been raised about a nuance of the GMS contracting arrangements which is the difference between a Personally Administered Item Submission Document and a Personally Administered Item Submission Document Annex.

The summary information document notes that inclisiran is available in general practice as a personally administered item reimbursed via an FP10 prescription. It also states that:

*“In addition to the typical approach of issuing an FP10 prescription to the patient to be dispensed via community pharmacy (see Point 3.3), a prescriber can order inclisiran directly from the wholesaler (AAH), administer to the patient and submit to the NHSBSA via the FP34D / FP34PD submission document for payment purposes.”*

It is important to note this is not referring to the FP34D/PD high volume appendix form e.g., which is used for vaccines. As such, inclisiran administration should not be entered on this but should be counted within the FP34D/PD submission documents.

As well as including within the FP34D/PD submission documents, it is important that practices submit an individual FP10 for each inclisiran injection as this will trigger payment for the dispensing fee and reimbursement of the drug cost. This is important as without the submission of the FP10 practices may not receive income they are due. If necessary GP practices can resubmit these prescriptions via the individual FP10 for payment.

For any general enquiries about inclisiran or other treatments within the lipid management pathway please contact [england.lipidsphm@nhs.net](mailto:england.lipidsphm@nhs.net)